Impact of Pre-ART Blood CD4+ T Cell Level on the Rectal Reservoir in Long-term HIV-1 Treated Men
NCT02526940 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30
Last updated 2015-11-02
Summary
Although combined antiretroviral therapy (cART) has dramatically improved quality of life and lifespan of HIV infected individuals, it still fails to eliminate viral reservoirs. The Gut Associated Lymphoid Tissue (GALT) is the largest reservoir of HIV-1, as it harbors most of HIV target cells as activated memory Cluster of differentiation (CD)4+/CCR5+ T cells. Intestinal T and B cells express α4β7 integrin, a gut mucosal homing receptor which binds to gp120 HIV-1 envelope facilitating the infection of intestinal T cells and the early establishment of the gut HIV reservoir. Intensive viral replication in the GALT leads to an early impairment of mucosal immunity, due to the severe CD4+ T cells depletion, that could be also explained by a lack of recruitment in the gut. Among T cells, interleukin-(IL-)17 secreting CD4+ T cells (Th17) are particularly depleted during HIV infection. This depletion could be associated with HIV progression since these cells play a crucial role in the maintenance of mucosal immunity. A dysbalance of the Th17/Treg ratio may reflect the loss of the intestinal epithelial barrier integrity. These damages are responsible for an increase in microbial translocation, which is associated with immune activation and progression to AIDS. Several recent studies have shown that cART initiation during acute or early HIV-1 infection reduces HIV DNA reservoir size and improves immune reconstitution in blood. Post-treatment controllers, who started long-term cART early after HIV infection, have very low levels of HIV DNA in peripheral blood mononuclear cells, similarly to elite controllers. Unlike most HIV-infected individuals, they maintain an undetectable plasmatic viral load after several years of cART interruption, suggesting that a weak reservoir is a prerequisite to achieve a functional cure. By extrapolation, it could be hypothesized that the gut viral reservoir is also decreased and that mucosal immunity is restored when cART is initiated during primary phase of infection. The gut viral reservoir begins to form within the first days after HIV exposure, and grows during acute HIV infection. Similarly, intestinal T cells are depleted very early after infection, due to high viral replication, host immune response and bystander effects. Most studies also concluded that long-term and optimal treatment can't fully restore mucosal immunity. These observations led us to study the impact of time of cART start on the size of viral reservoir and on immune reconstitution in the gut. For this, we analyzed the virological and immunological characteristics of the rectal HIV reservoir of long-term treated patients regarding their blood CD4+ T cells count at the time of cART initiation.
Conditions
- Human Immunodeficiency Virus
Interventions
- PROCEDURE
-
rectal biopsies
6 rectal biopsies
- OTHER
-
Blood samples
Blood samples
Sponsors & Collaborators
-
Centre Hospitalier Universitaire de Saint Etienne
lead OTHER
Principal Investigators
-
Frederic LUCHT, PhD · CHU SAINT-ETIENNE
Eligibility
- Min Age
- 18 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-05-31
- Primary Completion
- 2015-08-31
- Completion
- 2015-08-31
Countries
- France
Study Locations
More Related Trials
-
Optimization of HIV-1 DNA Genotyping by High Throughput Sequencing to Document Antiretroviral Resistant Mutations
NCT03512795 ·Status: COMPLETED
-
Ex Vivo Characterization and Targeting of the Latent HIV Infected Reservoir to Cure HIV
NCT05215704 ·Status: RECRUITING
-
Analytical Treatment Interruption in HIV Positive Patients
NCT02590354 ·Status: COMPLETED ·Phase: NA
-
HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in Spain
NCT00685191 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Dolutegravir Intensification on HIV-1 Reservoirs
NCT05351684 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment De-Intensification and Residual HIV-1 in Youth
NCT00867854 ·Status: COMPLETED
-
HIV Sequencing After Treatment Interruption to Identify the Clinically Relevant Anatomical Reservoir
NCT02641756 ·Status: COMPLETED ·Phase: NA
-
Residual Replication of HIV-1 in the Gut Associated Lymphoid Tissue (GALT) of Patients on Highly Active Antiretroviral Therapy (HAART): the ANRS EP 44 Study
NCT01038401 ·Status: COMPLETED ·Phase: NA
-
Evolution of HIV Reservoir, Inflammation and Microbiota Footprint of PLWH Switching to Long-acting Injectable Treatment Compared to Patients on Oral Dual or Triple Anti-integrase-based Therapy
NCT05303337 ·Status: RECRUITING
-
Raltegravir With Optimized Background Therapy (OBT) in Multiple Experienced HIV-infected Patients
NCT01190124 ·Status: COMPLETED
-
Raltegravir as Early Therapy in African-Americans Living With HIV Study
NCT00667433 ·Status: COMPLETED ·Phase: PHASE1
-
Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery
NCT00562510 ·Status: TERMINATED ·Phase: PHASE3
-
Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir Therapy
NCT00661960 ·Status: COMPLETED ·Phase: NA
-
ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy
NCT03122262 ·Status: COMPLETED ·Phase: PHASE3
-
Early ART to Limit Infection and Establishment of Reservoir
NCT02859558 ·Status: COMPLETED ·Phase: PHASE2
-
Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1
NCT00807443 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Explore Reconstitution of Immunity in Patients With Advanced HIV-1-infection
NCT01296373 ·Status: COMPLETED
-
Optimising Cohorts for HIV Cure Interventions
NCT05852301 ·Status: RECRUITING
-
Comparing Immune Activation and Latent HIV Reservoir Size Between People Living With HIV on Tenofovir-containing Versus NRTI-free ART
NCT05584397 ·Status: ENROLLING_BY_INVITATION
-
Same-Day HIV Testing and Treatment Initiation to Improve Retention in Care
NCT01900080 ·Status: UNKNOWN ·Phase: NA
-
Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients
NCT02995824 ·Status: COMPLETED
-
Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients
NCT02370979 ·Status: UNKNOWN ·Phase: PHASE4
-
Impact of Raltegravir on the Viral Reservoirs
NCT01249560 ·Status: UNKNOWN
-
Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection
NCT02656511 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy
NCT00709397 ·Status: TERMINATED